Salarius Pharmaceuticals (NASDAQ:SLRX) Releases Quarterly Earnings Results

Salarius Pharmaceuticals (NASDAQ:SLRX) issued its quarterly earnings data on Friday. The company reported ($0.66) earnings per share for the quarter, Zacks reports.

Salarius Pharmaceuticals Trading Up 6.4 %

SLRX stock traded up $0.06 on Friday, hitting $0.95. The company’s stock had a trading volume of 20,802 shares, compared to its average volume of 1,225,875. The firm has a 50 day moving average of $1.73 and a two-hundred day moving average of $1.61. Salarius Pharmaceuticals has a 1 year low of $0.83 and a 1 year high of $7.20. The stock has a market cap of $1.65 million, a price-to-earnings ratio of -0.12 and a beta of 0.59.

About Salarius Pharmaceuticals

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.